Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Kyverna Therapeutics, Inc. Common Stock

Healthcare US KYTX

7.47USD
-0.48(6.04%)

Last update at 2026-06-05T20:00:00Z

Day Range

7.447.96
LowHigh

52 Week Range

12.1535.06
LowHigh

Fundamentals

  • Previous Close 7.95
  • Market Cap0.00000M
  • Volume608933
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31
Income before tax -60.36600M -28.89300M -26.35000M
Minority interest - - -
Net income -60.36600M -28.89300M -26.35000M
Selling general administrative 12.48M 8.01M 6.15M
Selling and marketing expenses - - -
Gross profit - - -
Reconciled depreciation 1.71M 1.05M 0.59M
Ebit - - -
Ebitda - - -
Depreciation and amortization - - -
Non operating income net other - - -
Operating income -62.40600M -29.38400M -26.34600M
Other operating expenses - - -
Interest expense 0.19M 0.07M 0.00300M
Tax provision - - -
Interest income 2.28M 0.56M 0.00100M
Net interest income 2.10M 0.50M -0.00200M
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense - - -
Total revenue 0.00000M 7.03M 5.66M
Total operating expenses 62.41M 36.41M 32.00M
Cost of revenue - - -
Total other income expense net -0.05500M -0.00900M -0.00200M
Discontinued operations - - -
Net income from continuing ops -60.36600M -28.89300M -26.35000M
Net income applicable to common shares - - -
Preferred stock and other adjustments - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31
Total assets 75.19M 66.92M 85.49M
Intangible assets - - -
Earning assets - - -
Other current assets 3.12M 1.93M 1.02M
Total liab 206.59M 140.92M 131.74M
Total stockholder equity -131.39700M -73.99700M -46.25400M
Deferred long term liab - - -
Other current liab 3.52M 0.56M 0.57M
Common stock - - -
Capital stock 0.00000M 0.00000M 0.00000M
Retained earnings -136.04300M -75.67700M -46.78400M
Other liab - - -
Good will - - -
Other assets - - -
Cash 34.65M 37.73M 76.07M
Cash and equivalents - - -
Total current liabilities 19.86M 11.95M 15.93M
Current deferred revenue - - -
Net debt - - -
Short term debt - - -
Short long term debt - - -
Short long term debt total - - -
Other stockholder equity - - -
Property plant equipment - - -
Total current assets 60.66M 53.25M 77.09M
Long term investments - - -
Net tangible assets - - -
Short term investments 22.90M 13.59M 0.00000M
Net receivables - - -
Long term debt - - -
Inventory - - -
Accounts payable 4.36M 1.45M 0.77M
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other 3.92M 1.23M 0.59M
Deferred long term asset charges - - -
Non current assets total 14.53M 13.67M 8.40M
Capital lease obligations 9.08M 10.56M 5.55M
Long term debt total - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31
Investments -8.78500M -14.09700M -1.28900M
Change to liabilities - - -
Total cashflows from investing activities - - -
Net borrowings - - -
Total cash from financing activities 58.12M 11.88M 72.52M
Change to operating activities - - -
Net income -60.36600M -28.89300M -26.35000M
Change in cash -3.07700M -38.33000M 49.08M
Begin period cash flow 38.29M 76.62M 27.54M
End period cash flow 35.21M 38.29M 76.62M
Total cash from operating activities -52.41000M -36.11300M -22.15500M
Issuance of capital stock 59.90M 11.95M 72.53M
Depreciation 1.71M 1.05M 0.59M
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock - - -
Other cashflows from financing activities - - -
Change to netincome - - -
Capital expenditures 0.62M 0.77M 1.29M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 3.42M -10.32700M -4.49100M
Stock based compensation 2.22M 0.93M 7.25M
Other non cash items 1.72M 1.41M 0.83M
Free cash flow -53.03100M -36.88100M -23.44400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
KYTX
Kyverna Therapeutics, Inc. Common Stock		 -0.48 6.04% 7.47 - - - -
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Kyverna Therapeutics, Inc. Common Stock

5980 Horton Street, Emeryville, CA, United States, 94608

Key Executives

Name Title Year Born
Dr. Peter Maag Ph.D. CEO & Director 1967
Ms. Karen Walker Chief Technology Officer 1962
Dr. James Chung M.D., Ph.D. Chief Medical Officer 1968
Mr. Ryan Jones Chief Financial Officer 1988
Dr. Tom Van Blarcom Ph.D. Senior VP & Head of Research NA
Ms. Portia Serame Vice President of Human Resources NA
Dr. Dominic Borie M.D., Ph.D. President of Research & Development 1963
Mr. Devin Murray Senior Vice President of Partnerships & Alliances NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions